TY - JOUR
T1 - Immunotherapy and cardiovascular diseases
T2 - novel avenues for immunotherapeutic approaches
AU - Bonfiglio, C. A.
AU - Weber, C.
AU - Atzler, D.
AU - Lutgens, E.
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - As current therapies for cardiovascular disease (CVD), predominantly based on lipid lowering, still face an unacceptable residual risk, novel treatment strategies are being explored. Besides lipids, inflammatory processes play a major role in the pathogenesis of atherosclerosis, the underlying cause of the majority of CVD. The first clinical trials targeting the interleukin-1β-inflammasome axis have shown that targeting this pathway is successful in reducing cardiovascular events but did not decrease overall CVD mortality. Hence, novel and improved immunotherapeutics to treat CVD are being awaited.
AB - As current therapies for cardiovascular disease (CVD), predominantly based on lipid lowering, still face an unacceptable residual risk, novel treatment strategies are being explored. Besides lipids, inflammatory processes play a major role in the pathogenesis of atherosclerosis, the underlying cause of the majority of CVD. The first clinical trials targeting the interleukin-1β-inflammasome axis have shown that targeting this pathway is successful in reducing cardiovascular events but did not decrease overall CVD mortality. Hence, novel and improved immunotherapeutics to treat CVD are being awaited.
UR - http://www.scopus.com/inward/record.url?scp=85134511350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134511350&partnerID=8YFLogxK
U2 - 10.1093/qjmed/hcab207
DO - 10.1093/qjmed/hcab207
M3 - Review article
C2 - 34293177
AN - SCOPUS:85134511350
SN - 1460-2725
VL - 116
SP - 271
EP - 278
JO - QJM: An International Journal of Medicine
JF - QJM: An International Journal of Medicine
IS - 4
ER -